NEW YORK, July 11, 2018 /PRNewswire/ -- Neurotrope, Inc.
(NASDAQ: NTRP), a clinical-stage biopharmaceutical company
developing novel therapies for neurodegenerative diseases,
including Alzheimer's disease (AD), is announcing that it has
established its Scientific Advisory Board (SAB) comprised of
experts in the fields of AD and other Neurological diseases.
Dr. Martin R. Farlow, MD,
Professor Emeritus in the Department of Neurology at Indiana University and co-director of the
Alzheimer's Disease Center at Indiana
University, will serve as Chairperson of the SAB. Dr.
Farlow has authored numerous peer reviewed scientific publications
and was lead investigator of the trial showing the first time
memantine, when added to donepezil in combination, demonstrated a
statistically significant benefit as compared to donepezil alone. A
more complete description of Dr. Farlow's accomplishments is
included below.
"We are delighted to have leading authorities in the field of
Alzheimer's research and clinical design and analysis agree to join
our Scientific Advisory Board," said Neurotrope CEO Charles Ryan. "We believe that this team of
accomplished leading academicians will enhance our company's
ability to accelerate the development of bryostatin in Alzheimer's
Disease and other neurological disorders, expand our pipeline with
the right strategic assets, and advance our goal to bring a novel
therapeutic to the market to treat patients with AD and other
neurological disorders."
"Bryostatin has a new and unique mechanism of action with the
potential to perhaps increase cognition, as opposed to simply
slowing the progression of Alzheimer's disease," said Dr.
Martin Farlow, Scientific Advisory
Board Chair. "I look forward to working with Neurotrope and
the distinguished members of Neurotrope's Scientific Advisory Board
to develop a platform with a novel mechanism of action to advance
therapies for AD."
"The newly established SAB is a key strategic resource for
Neurotrope, providing scientific expertise and guidance to our team
as we advance the clinical development of bryostatin in AD while
continuing to assess the use
of bryostatin to potentially treat other diseases,"
stated Dr. Ryan.
Scientific Advisory Board Chairperson & Members
Martin R. Farlow,
(Chairperson) MD, Professor Emeritus in the Department of Neurology
at Indiana University and co-director
of the Alzheimer's Disease Center at Indiana
University, will serve as chair of the SAB. Dr. Farlow
received his medical degree from Indiana
University School of Medicine. Following graduation,
he completed an internship in Internal Medicine and a residency in
Neurology.
Dr. Farlow's research focuses on clinical trials of
investigational drugs for the treatment of AD and related dementias
and has been the lead investigator for several major studies
including tacrine, donepezil and rivastigmine. Dr. Farlow has
authored numerous peer reviewed scientific publications and
lectured on the topics of aging, dementia, and Alzheimer's disease
at more than 300 meetings, conferences, and hospitals/medical
schools throughout the world. He is a reviewer for numerous
scientific journals and on the editorial boards of MedLink and
Current Alzheimer Research. Dr. Farlow is a member of many
professional associations including the American Academy of
Neurology and the American Neurological Association. He is also a
founding member of both the American Society of Experimental
Neurotherapeutics and the International Society for CNS Clinical
Trials and Methodology.
Paul Coleman PhD, has been
an Associate at the University of
Arizona (UA) McKnight Brain Institute since 2010 and a
Research Professor at the UA Biodesign Institute since 2015.
In 2007, Dr. Coleman was appointed Professor Emeritus at the
University of Rochester Medical
Center. Since 1988, Dr. Coleman has served as Editor-in-Chief
for the journal Neurobiology of Aging and is currently Editor
Emeritus and an Advisory Editor. Dr. Coleman received an AB
in Psychology (magna cum laude) from Tufts
University and a PhD in Physiology and Psychology from the
University of Rochester. Following his PhD, Dr. Coleman was
supported by the National Institute of Neurological Disorders and
Stroke as a Special Fellow at Johns Hopkins School of
Medicine.
Dr. Coleman has been a pioneering investigator of the pathologic
basis of AD. His work has provided insight into how synaptic
network loss and dysfunction are correlated with cognitive
decline. His early work examined dynamic processes of
synaptic plasticity. At Cold Spring Harbor Laboratory, he developed
a method for profiling gene expression in single cells in vitro
which he subsequently applied to the postmortem human brain using
both mRNA and in situ hybridization methods. Dr. Coleman published
one of the first studies profiling gene expression of single
neurons in the Alzheimer versus normal human brain. Dr.
Coleman is the recipient of numerous awards including the
LEAD Award: Leadership and Excellence in Alzheimer's disease from
NIH/NIA in 1990 to 1999 (one of 12 ever given), an Honorary
Professorship from the Jilin Medical College in Jilin China in 1988 and a Pioneer Award: from
the National Alzheimer's and Related Disorders Association (1999 –
2004).
Daniel F. Hanley Jr. MD,
has been a Professor of Neurology, Neurosurgery and Anesthesia and
Critical Medicine at Johns Hopkins Medicine since 1996. He is
a graduate of Williams College and
received his medical degree from Cornell
University Medical College. Dr. Hanley has board
certification in internal medicine, neurology and psychiatry.
Dr. Hanley is a leading expert on brain injury and has received
more than 20 basic research grants, predominantly from the National
Institute of Health. He received the Alexander Humboldt
Research Prize for his accomplishments in brain injury research,
where he has extensive clinical trials experience. Dr. Hanley
also received the 2018 Distinguished Investigator Award from the
American College of Critical Care Medicine. He is the Vice
Chairman of the Board of Directors of the National Stroke
Association and the Jeffrey and Harriett Legum Professor of Acute
Care Neurology and Director of Brain Injury Outcomes Program.
Serving on the board of Directors of the National Stroke
Association, Dr. Hanley leads the Johns
Hopkins – Tufts Trial
Innovation Center an NIH supported center dedicated to
improving the efficiency and quality of clinical trials. He
has published more than 300 articles in peer-reviewed
journals. Dr. Hanley is a member of the American Academy of
Neurology, American Neurological Association, Neurocritical Care
Society and the Society of Critical Care Medicine. He served
as associate editor for Stroke, Critical Care Medicine, and on the
board of International Journal of Stroke. He also serves as a
reviewer for multiple peer-reviewed journals.
Marwan Sabbagh, MD,
is the new director of the Cleveland Clinic Lou Ruvo Center for
Brain Health and he has dedicated his entire career to finding a
cure for Alzheimer's and other age-related neurodegenerative
diseases. Dr. Sabbagh earned his undergraduate degree from
the University of California-Berkeley
and his medical degree from the University of
Arizona in Tucson.
Dr. Sabbagh received his residency training in neurology at
Baylor College of Medicine and
completed his fellowship training in geriatric neurology and
dementia under renowned AD experts, Leon
Thal, M.D., and Robert
Katzman, M.D., at the University of
California, San Diego School of Medicine. Dr. Sabbagh is a
board-certified neurologist and geriatric neurologist.
Dr. Sabbagh is a leading investigator for many prominent
national Alzheimer's prevention and treatment trials, including
Alzheimer immunotherapy studies. He is on the editorial board
of the Journal of Alzheimer's Disease, Alzheimer's Disease
and Associated Disorders, Current Alzheimer's Research, American
Journal of Alzheimer's and Dementia and BMC
Neurology. He has authored and co-authored more than 300
medical and scientific articles on Alzheimer's research. Dr.
Sabbagh authored The Alzheimer's Answer—the book's
forward was written by Justice Sandra Day O'Connor—and The
Alzheimer's Prevention Cookbook: 100 Recipes to Boost Brain
Health. Dr. Sabbagh edited Palliative Care
for Advanced Alzheimer's and Dementia: Guidelines and Standards
for Evidence Based Care, and Geriatric
Neurology. Dr. Sabbagh is
also Editor-in-Chief of the Neurology and
Therapy Journal, an international, open access,
peer-reviewed, rapid publication journal dedicated to the
publication of high-quality preclinical, clinical (all phases),
observational, real-world, and health outcomes research around the
discovery, development, and use of neurological and psychiatric
therapies, including devices.
Lee Jen Wei, PhD,
is a tenured Professor of Biostatistics at Harvard University since 1991. He was the
co-director of the Bioinformatics Core at the Harvard School of
Public Health. Dr. Wei obtained his B.S in mathematics from
Fu-Jen University (Taiwan) and his
PhD in statistics from the University of Wisconsin–Madison.
In 1986, Dr. Wei was elected as a Fellow of the American
Statistical Association. Professor Wei was named
"Statistician of the Year" in 2007 by the Boston Chapter of the
American Statistical Association.
The American Statistical Association gave him
the Wilks Memorial Award in 2009 "for statistical methods
used in clinical trials," which is one of the most prestigious
awards among all the international statistical societies.
Professor Wei has developed and published a number of novel
quantitative methods for analyzing data from experimental and
observational studies. Specifically, Dr. Wei has published
many papers on monitoring drug and device safety and related
topics. The resulting procedures have been utilized for
various drug and device regulatory evaluations involving safety
issues. His extensive experience in quantitative science for making
inferences about the drug and device safety is readily applicable
to the general industry product safety issues. Professor
Wei's scholarly writings include over 130 articles in peer-reviewed
academic journals. He is responsible for developing numerous
novel statistical methods for practitioners. Many of these
methods have been included in the most commonly used statistical
packages. He has additionally served on the editorial boards
of a number of statistical journals and is an elected Fellow of the
American Statistical Association and Institute of Mathematical
Statistics.
About Neurotrope
Neurotrope is at the forefront of developing a new approach to
combating AD and other neurodegenerative diseases. The
Company's world-class science offers the potential to realize a
paradigm shift to overcome one of today's most challenging clinical
problems finding a way to slow or even prevent the progression of
AD.
In addition to the Company's Phase 2 trial of Bryostatin-1 in
advanced AD, Neurotrope has also conducted preclinical studies of
bryostatin as a potential treatment for Fragile X Syndrome, Stroke,
Traumatic Brain Injury, and Niemann-Pick Type C disease and Rett
Syndrome—rare genetic diseases for which only symptomatic
treatments are currently available. The FDA has granted Orphan Drug
Designation to Neurotrope for Bryostatin-1 as a treatment for
Fragile X Syndrome. Bryostatin-1 has already undergone testing
in more than 1,500 people in cancer studies, thus creating a large
safety data base that will further inform clinical trial designs in
AD.
Please visit www.neurotrope.com for further
information.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 study and further studies, and continued
development of use of Bryostatin-1 for Alzheimer's dementia and
other cognitive diseases. Such forward-looking statements are
subject to risks and uncertainties and other influences, many of
which the Company has no control over. These statements are subject
to the risk that further analyses of the Phase 2 data may lead to
different interpretations of the data than the analyses conducted
to date and/or may identify important implications of the Phase 2
data that are not reflected in these statements. Clinical trial
data are subject to differing interpretations, and regulatory
agencies, medical and scientific experts and others may not share
the Company's views of the Phase 2 data. There can be no assurance
that the clinical program for Bryostatin-1 will be successful in
demonstrating safety and/or efficacy that we will not encounter
problems or delays in clinical development, or that Bryostatin-1
will ever receive regulatory approval or be successfully
commercialized. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Additional factors that may influence or cause
actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time
associated with drug development and related insufficient cash
flows and resulting illiquidity, the Company's patent portfolio,
the Company's inability to expand the Company's business,
significant government regulation of pharmaceuticals and the
healthcare industry, lack of product diversification, availability
of the Company's raw materials, existing or increased
competition, stock volatility and illiquidity, and the
Company's failure to implement the Company's business plans or
strategies. These and other factors are identified and described in
more detail in the Company's filings with the SEC, including the
Company's Annual Report on Form 10-K for the year
ended December 31,
2017, and on Form 10-Q for the quarter ending
March 31, 2018. The Company
does not undertake to update these forward-looking
statements.
Contact information:
Investors and Media
Jeffrey Benison, Director of Corporate Communications
Neurotrope, Inc.
516.286.6099 (C) or 212.334.8709 (O)
jbenison@neurotrope.com
View original
content:http://www.prnewswire.com/news-releases/neurotrope-appoints-leading-experts-in-alzheimers-disease-to-its-scientific-advisory-board-sab-300679027.html
SOURCE Neurotrope, Inc.